Showing results (111-120 of 180) with videos related to
Sort By:
Pageof 18
Cancer Medicine|April 13, 2026
Second Line Treatment Decision as Per Standard of Care or Foundation Medicine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerFederico Rojo, Enriqueta Felip, Oscar Juan Vidal, et al.Clinical Epigenetics|March 22, 2021
Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patientsRocio Rosas-Alonso, Julian Colmenarejo-Fernandez, Olga Pernia, et al.Clinical Drug Investigation|July 31, 2024
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung CancerEdurne Arriola, Javier de Castro, Rosario García-Campelo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2023
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)Ernest Nadal, Delvys Rodríguez-Abreu, Marta Simó, et al.International Journal of Molecular Sciences|July 29, 2023
miR-124 as a Liquid Biopsy Prognostic Biomarker in Small Extracellular Vesicles from NSCLC PatientsDarío Sanchez-Cabrero, Álvaro Garcia-Guede, Miranda Burdiel, et al.Molecular and Clinical Oncology|July 3, 2015
Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE studyJavier DE Castro Carpeño, Pere Gascón-Vilaplana, Ana Maria Casas-Fernández-DE Tejerina, et al.Oncotarget|June 20, 2022
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access programReyes Bernabé-Caro, Pilar Garrido, Rosario García-Campelo, et al.Lung Cancer (Amsterdam, Netherlands)|December 25, 2025
Optimizing communication for ultrafast lung cancer biomarker testing: the UTOPIA pilot studySusana Hernandez, Esther Conde, Marta Alonso, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 12, 2025
PD-L1 expression scoring using artificial intelligence algorithms in non-small cell lung cancer harbouring ROS1 fusions: potential clinical-biological significanceLuis Fernando García, Esther Conde, Susana Hernandez, et al.Cancer Letters|June 26, 2009
MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancerMaría Cortes-Sempere, Sharmila Chattopadhyay, Ana Rovira, et al.Pageof 18